Arkolith/Funds/Euclidean Capital LLC

Euclidean Capital LLC

CIK 1825034
Holdings as of Mar 31, 2026·disclosed May 15, 2026·~45-day 13F lag·13F-HR
Active Filer

Euclidean Capital LLC holds a concentrated book of 10 stocks worth $392.3M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). Their largest long position is Vanguard Ftse All-World Ex-U at 62% of the equity book.

Build

Build on this 13F portfolio

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.

Build

Ask your agent what Euclidean Capital LLC owns

This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/funds/1825034/holdings"
Ask your agent
Use Arkolith to show Euclidean Capital LLC's latest
holdings, largest changes, and filing provenance.
Opened
0
new positions
Added to
1
existing
Trimmed
0
reduced
Sold out
2
exited

Concentration

Top-heavy: concentrated book

Top 5 holdings
98%
Top 10 holdings
100%
Top 20 holdings
100%

Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.

Direct sector allocation

7% mapped to company sectors

ETF / fund or unclassified
93%
Health Care
7%

Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.

Biggest moves: latest quarter

Estimated $ traded · quarter-end prices, no cost basis

Bought
Trimmed / exited

Holdings: largest first

Bars show each stock's share of the portfolio. Click a row for its position history.

10 positions
#SecurityValueShares% PortLast moveHistory
1Vanguard Intl Equity Index F
ALLWRLD EX US
$243.6M3.24M
62.1%
+8.5%
Added · +253K sh
2Vanguard Index FDS
VALUE ETF
$102.0M520.0K
26.0%
Held
3Ishares TR
MSCI INDIA ETF
$17.3M369.6K
4.4%
Held
4Oric Pharmaceuticals Inc
COM
$12.5M989.4K
3.2%
Held
5Foghorn Therapeutics Inc
COM
$7.5M1.57M
1.9%
Held
6PMV Pharmaceuticals Inc
COM
$3.3M2.63M
0.8%
Held
7Alector Inc
COM
$2.8M1.31M
0.7%
Held
8Surrozen Inc
COM NEW
$2.6M87.7K
0.7%
Held
9Tenaya Therapeutics Inc
COM
$703K1.02M
0.2%
Held
10Surrozen Inc
*W EXP 08/01/203
$3K170.8K
0.0%
Held
Showing all 10 positions

Filing history

As-of date vs the date the SEC received each filing

QuarterAs ofFiledPositionsValueForm
Q1 2026Mar 31, 2026May 15, 202610$392.3M13F-HR
Q4 2025Dec 31, 2025Feb 17, 202612$369.5M13F-HR
Q3 2025Sep 30, 2025Nov 14, 202511$238.0M13F-HR
Q2 2025Jun 30, 2025Aug 14, 202511$305.7M13F-HR

Data source

Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.